AtheroMed secured 510(k) clearance from the FDA for its Phoenix device, an atherectomy catheter used for treating peripheral artery disease.
The low-profile catheter aims to minimizes vessel interaction and designed to be easy to set up. The Phoenix system features front-cutting technology that cuts while clearing away clearing debris with an internal Archimedes screw, which runs the length of the catheter. The device is available in a variety of sizes, according to a press release.
AtheroMed is closing in on a $4.5 million fundraising round, offering debt and options offering, SEC documents show.
The Menlo Park, Calif.-based medical device company has so far raised $4.3 million for its operations, according to a regulatory filing.
AtheroMed said it’s raised a $6 million equity round, taking its total funding raise since 2009 to $20 million, according to regulatory filings.
The Menlo Park, Calif.-based medical device company is developing an atherectomy device for treating peripheral artery disease, according to its website.
AtheroMed is still flying under the radar, to judge by the 1-page website, which provides only an email link to contact the company.